Bao SX, Yuan XL, Yan L, Xu J. Pegaspargase induced multiple organ failure with acute lymphoblastic leukemia: A case report. World J Clin Cases 2025; 13(13): 100735 [DOI: 10.12998/wjcc.v13.i13.100735]
Corresponding Author of This Article
Jie Xu, MAMS, Chief Doctor, Department of Infectious Disease, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, No 280 Mohe Road, Baoshan District, Shanghai 201900, China. dr.xu@aliyun.com
Research Domain of This Article
Hematology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Pegaspargase induced multiple organ failure with acute lymphoblastic leukemia: A case report
Su-Xia Bao, Xiao-Ling Yuan, Lei Yan, Jie Xu
Su-Xia Bao, Xiao-Ling Yuan, Lei Yan, Jie Xu, Department of Infectious Diseases, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China
Author contributions: Bao SX, Yuan XL and Xu J contributed to research design; Bao SX, Yuan XL, Yan L and Xu J contributed to data acquisition; Bao SX contributed to manuscript writing and funding; Yuan XL, Yan L and Xu J contributed to critical revision; Xu J contributed to administration and technical support.
Supported by National Natural Science Foundation of China, No. 82100625, and Zhejiang Provincial natural Science Foundation of China, No. Q20H030013.
Informed consent statement: The patient agreed to the publication of the case study, and provided written informed consent.
Conflict-of-interest statement: The authors declare that there are no conflicts of interest regarding the publication of this paper.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jie Xu, MAMS, Chief Doctor, Department of Infectious Disease, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, No 280 Mohe Road, Baoshan District, Shanghai 201900, China. dr.xu@aliyun.com
Received: August 24, 2024 Revised: November 10, 2024 Accepted: December 9, 2024 Published online: May 6, 2025 Processing time: 139 Days and 21.8 Hours
Abstract
BACKGROUND
The introduction of pegaspargase has greatly advanced the treatment of acute lymphoblastic leukemia (ALL). In the literature, only one case of pegaspargase-induced multiple organ failure has been reported, and the patient died due to multiple organ failure.
CASE SUMMARY
Herein, we present a rare case of a 40-year-old man with ALL who developed multiple organ failure after treatment with pegaspargase. The patient had two rare phenomena reflecting poor prognosis, including the discrepancy between clinical manifestations and liver function and persistently low alpha-fetoprotein (AFP) levels from subacute liver failure. However, the patient was successfully treated using a multidisciplinary team approach.
CONCLUSION
This is the first case report of successful treatment of pegaspargase-induced multiple organ failure. The findings emphasize the importance of a multidisciplinary team approach in treating pegaspargase-induced multiple organ failure.
Core Tip: We reported a rare patient with acute lymphoblastic leukemia, who suffered from multiple organ failure following the first application of pegaspargase. To date, only one patient has been reported and the patient died due to multiple organ failure in the reviewed word literature. In the article, although the patient had two rare phenomena reflecting poor prognosis, the patient was the first case of successful treatment. Two rare phenomena including inconformity between clinical manifestation and liver function, and persistent low AFP concentrations from subacute liver failure patients will be discussed in this patient.
